450 Klin Onkol 2020; 33(6): 450– 457 ORIGINAL ARTICLE A Ukrainian multicenter prospective study of the value of PET/CT prognostic role in primary patients with Hodgkin’s lymphoma in a real-life cohort Ukrajinská multicentrická prospektivní studie hodnoty prognostické role PET/CT u primárních pacientů s Hodgkinovým lymfomem v kohortě z reálného života Novosad O. 1 , Skrypets T. 1 , Pastushenko I. 1 , Kadnikova T. 1 , Gorbach O. 1 , Kozlov V. 2 , Mykhalska L. 3 , Kosinova V. 4 , Kostiukova N. 5 , Karnabeda O. 6 , Stratienko V. 7 , Novikov M. 4 , Oliinichenko O. 8 , Kmetyuk I. 9 , Karpova O. 9 , Ashykhmin A. 10 , Lukjanec O. 11 , Kriachok I. 1 1 Oncology and Hematology, National Cancer Institute, Kyiv, Ukraine 2 Regional Clinical Hospital, Odessa, Ukraine 3 Center of Hematology, Feofaniya Clinical Hospital, Kyiv, Ukraine 4 Oncology Hospital “LISOD”, Kyiv, Ukraine 5 Kyiv Centre of Bone Marrow Transplantation, Kyiv, Ukraine 6 Hospital of Oncology “Innovacia”, Kyiv, Ukraine 7 Regional Clinical Hospital, Kherson, Ukraine 8 Center of Nuclear Medicine, Kyiv, Ukraine 9 Feofaniya Clinical Hospital, Kyiv, Ukraine 10 Radiology, National Cancer Institute, Kyiv, Ukraine 11 Cherkassy Regional Oncology Center, Cherkasy, Ukraine Summary Introduction: In recent years, the positron emission tomography combined with computed tomo- graphy (PET/CT) has changed and the treatment approaches in Hodgkin’s lymphoma (HL) patients have entirely improved. The main idea in several studies is the use of PET/CT and the International Prognostic Score (IPS) protocols in identifcation of patients within a high-risk group and potential early relapse/refractory disease. Materials and methods: This study was based on PET/CT evaluation and treatment strategies of patients from eight Centers of Hematology in Ukraine. The patients inclu- ded were newly diagnosed with HL and were aged 67 years or younger. They received a treatment with ABVD or BEACOPP-14/esc or “switched-regimens” (ABVD + BEACOPP-esc/14, BEACOPP- -esc/14 + ABVD). The primary endpoints were to assess a correlation between PET/CT fndings at the time of diagnosis, response to the therapy and clinical outcome (relapse/death) for patients with early and advanced stages of HL. The secondary endpoints were to evaluate the relationship between IPS and PET/CT fndings. Results: The study group included 106 patients. The overall response rate (ORR) was 90.5%. The ORR for patients with stages I–II was 96.5% (55/57) vs. 91% (41/45) for stage III–IV patients. In total, the disease progression occurred in 58.3% (7/12) of PET2+ patients and in 13.3% (12/90) of PET2− patients (P < 0.05). No signifcant diference was found between the event free sur- vival (EFS) rate and IPS for patients with PET2+ vs. PET2−, (log-rank test; P = 0.4). The PET3− status was found in 88.8% (79/89) of the study group patients and 1.2% (10/89) had a PET3+ status (P < 0.05). Using the Cox regression, we confrmed a signifcant correlation between EFS with PET3 Deauville scale (DS) and IPS. Patients with DS 1–2, DS 3 and DS 4–5 had a 1-year event-free survival of 94.4%, 100% and 33%, respectively (HR 0.56; 95% CI 1.07–2.8; P < 0.02). Our multivariable analysis showed no statistically signifcant correlation between PET2+ and PET3+ status and extranodal involvement or large tumor burden. Conclusion: The results of using PET/CT in patients with primary HL demon- strated a high prognostic value of PET at the end of the treatment. In addition, we confrmed the predictive role of IPS prognostic model in the treatment outcome depending on PET status. Key words Hodgkin’s lymphoma – positron emission tomography – prognosis – survival This research did not receive any funds from private, public or non-proft sector. We thank all our colleagues who treated pa- tients from eight Ukrainian Centers: Irina Ty- torenko, Olena Aleksik, Yana Stepanishina, Katerina Filonenko, Arina Martynchyk, Kate Uli- anchenko, Evgeniy Kushchevyy and Oksana Tkachenko. The authors declare they have no potential conflicts of interest concerning drugs, pro- ducts, or services used in the study. Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy. The Editorial Board declares that the manu- script met the ICMJE recommendation for biomedical papers. Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do bi omedicínských časopisů.  Olga Novosad Department of Oncohematology National Cancer Institute 33/43 Lomonosova street 03022 Kiev Ukraine e-mail: novosad.o.ua@gmail.com Submitted/Obdrženo: 17. 2. 2020 Accepted/Přijato: 15. 6. 2020 doi: 10.48095/ccko2020450